Start a planned U.S.-based Phase 1 clinical trial of OTX-TKI
Delivered after the deadline (29 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- 29 Jul 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“A planned U.S.-based Phase 1 clinical trial is anticipated to start in mid-2021 and to consist of 20 subjects”
What we found
Evidence strength A What the grades mean
The company announced initiation of the U.S. Phase 1 OTX-TKI trial on July 29, 2021, after the June 30, 2021 deadline, with a planned 20 subjects.
-
A Ocular Therapeutix, Inc. 8-K filed 2021-08-09
“The Company dosed the first subject in the U.S.-based Phase 1 clinical trial” ✓ confirmed on the page
-
A Ocular Therapeutix, Inc. 10-Q filed 2021-08-09
“On July 29, 2021, we announced the initiation of a prospective, multi-center, randomized, controlled Phase 1 clinical trial in the United States” ✓ confirmed on the page
-
A Ocular Therapeutix, Inc. 10-Q filed 2021-08-09
“The trial will consist of 20 patients in two arms” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Start
- Deliverable
- U.S.-based Phase 1 trial of OTX-TKI
- Target
- 20 subjects
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Ocular Therapeutix, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-OCUL-025607 · Corrections policy